MIM
PRLD icon

MetLife Investment Management’s Prelude Therapeutics PRLD Stock Holding History

MetLife Investment Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4,148
Closed -$130K – 2541
2021
Q3 		$130K Hold
4,148
– – ﹤0.01% 2326
2021
Q2 		$119K Hold
4,148
– – ﹤0.01% 2392
2021
Q1 		$180K Buy
4,148
+29
+0.7% +$1.92K ﹤0.01% 2111
2020
Q4 		$295K Buy
+4,119
New +$205K ﹤0.01% 1779

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MetLife Investment Management's PRLD Position: Q4 2021 in Review

MetLife Investment Management sold out of Prelude Therapeutics (PRLD) in Q4 2021, closing a stake of 4,148 shares — an estimated $130K sold.

MetLife Investment Management first reported a position in PRLD in Q4 2020 and held it in 4 quarters. The position peaked at $295K in Q4 2020. 75 funds tracked by Wall St. Rank hold PRLD as of Q4 2021.

  • MetLife Investment Management reported no remaining Prelude Therapeutics position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 4,148 Prelude Therapeutics shares in Q4 2021, an estimated $130K.
  • MetLife Investment Management first reported a position in Prelude Therapeutics in Q4 2020 and held it in 4 quarters.
  • MetLife Investment Management's Prelude Therapeutics position peaked at $295K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.